Information de reference pour ce titreAccession Number: | 00006114-201510060-00012.
|
Author: | Palmqvist, Sebastian MD, PhD; Zetterberg, Henrik MD, PhD; Mattsson, Niklas MD, PhD; Johansson, Per MD, PhD; For the Alzheimer's Disease Neuroimaging Initiative; Minthon, Lennart MD, PhD; Blennow, Kaj MD, PhD; Olsson, Mattias PhD; For the Swedish BioFINDER study group; Hansson, Oskar MD, PhD
|
Institution: | Authors' affiliations are provided at the end of the article.
|
Title: | |
Source: | Neurology. 85(14):1240-1249, October 6, 2015.
|
Abstract: | Objective: To compare the diagnostic accuracy of CSF biomarkers and amyloid PET for diagnosing early-stage Alzheimer disease (AD).
Methods: From the prospective, longitudinal BioFINDER study, we included 122 healthy elderly and 34 patients with mild cognitive impairment who developed AD dementia within 3 years (MCI-AD). [beta]-Amyloid (A[beta]) deposition in 9 brain regions was examined with [18F]-flutemetamol PET. CSF was analyzed with INNOTEST and EUROIMMUN ELISAs. The results were replicated in 146 controls and 64 patients with MCI-AD from the Alzheimer's Disease Neuroimaging Initiative study.
Results: The best CSF measures for identifying MCI-AD were A[beta]42/total tau (t-tau) and A[beta]42/hyperphosphorylated tau (p-tau) (area under the curve [AUC] 0.93-0.94). The best PET measures performed similarly (AUC 0.92-0.93; anterior cingulate, posterior cingulate/precuneus, and global neocortical uptake). CSF A[beta]42/t-tau and A[beta]42/p-tau performed better than CSF A[beta]42 and A[beta]42/40 (AUC difference 0.03-0.12, p < 0.05). Using nonoptimized cutoffs, CSF A[beta]42/t-tau had the highest accuracy of all CSF/PET biomarkers (sensitivity 97%, specificity 83%). The combination of CSF and PET was not better than using either biomarker separately.
Conclusions: Amyloid PET and CSF biomarkers can identify early AD with high accuracy. There were no differences between the best CSF and PET measures and no improvement when combining them. Regional PET measures were not better than assessing the global A[beta] deposition. The results were replicated in an independent cohort using another CSF assay and PET tracer. The choice between CSF and amyloid PET biomarkers for identifying early AD can be based on availability, costs, and doctor/patient preferences since both have equally high diagnostic accuracy.
Classification of evidence: This study provides Class III evidence that amyloid PET and CSF biomarkers identify early-stage AD equally accurately.
(C) 2015 American Academy of Neurology
|
References: | 1. Albert MS, DeKosky ST, Dickson D, et al.. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:270-279.
2. Sperling RA, Aisen PS, Beckett LA, et al.. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:280-292.
3. Blennow K, Zetterberg H, Haass C, Finucane T. Semagacestat's fall: where next for AD therapies? Nat Med 2013;19:1214-1215.
4. Eli Lilly and Company. Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo (EXPEDITION 3). In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine. Cited January 20, 2015. Available at: https://clinicaltrials.gov/ct2/s...- ouverture dans une nouvelle fenêtre. NLM Identifier: NCT01900665.
5. Karran E, Hardy J. Antiamyloid therapy for Alzheimer's disease: are we on the right road? N Engl J Med 2014;370:377-378.
6. Seppala TT, Nerg O, Koivisto AM, et al.. CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings. Neurology 2012;78:1568-1575.
7. Wolk DA, Grachev ID, Buckley C, et al.. Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology. Arch Neurol 2011;68:1398-1403.
8. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010;6:131-144.
9. Buerger K, Ewers M, Pirttila T, et al.. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 2006;129:3035-3041.
10. Degerman Gunnarsson M, Lindau M, Wall A, et al.. Pittsburgh compound-B and Alzheimer's disease biomarkers in CSF, plasma and urine: an exploratory study. Dement Geriatr Cogn Disord 2010;29:204-212.
11. Fagan AM, Mintun MA, Mach RH, et al.. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006;59:512-519.
12. Fagan AM, Mintun MA, Shah AR, et al.. Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. EMBO Mol Med 2009;1:371-380.
13. Forsberg A, Almkvist O, Engler H, Wall A, Langstrom B, Nordberg A. High PiB retention in Alzheimer's disease is an early event with complex relationship with CSF biomarkers and functional parameters. Curr Alzheimer Res 2010;7:56-66.
14. Grimmer T, Riemenschneider M, Forstl H, et al.. Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol Psychiatry 2009;65:927-934.
15. Jagust WJ, Landau SM, Shaw LM, et al.. Relationships between biomarkers in aging and dementia. Neurology 2009;73:1193-1199.
16. Koivunen J, Pirttila T, Kemppainen N, et al.. PET amyloid ligand [11C]PIB uptake and cerebrospinal fluid beta-amyloid in mild cognitive impairment. Dement Geriatr Cogn Disord 2008;26:378-383.
17. Landau SM, Lu M, Joshi AD, et al.. Comparing PET imaging and CSF measurements of A[beta]. Ann Neurol 2013;74:826-836.
18. Mattsson N, Insel P, Donohue M, et al.. Independent information from cerebrospinal fluid [beta]-amyloid and florbetapir imaging in Alzheimer's disease. Brain 2015;138:772-783.
19. Mattsson N, Insel P, Landau S, et al.. Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease. Ann Clin Transl Neurol 2014;1:534-543.
20. Palmqvist S, Zetterberg H, Blennow K, et al.. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid beta-amyloid 42: a cross-validation study against amyloid positron emission tomography. JAMA Neurol 2014;71:1282-1289.
21. Tolboom N, van der Flier WM, Yaqub M, et al.. Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding. J Nucl Med 2009;50:1464-1470.
22. Weigand SD, Vemuri P, Wiste HJ, et al.. Transforming cerebrospinal fluid Abeta42 measures into calculated Pittsburgh Compound B units of brain Abeta amyloid. Alzheimers Dement 2011;7:133-141.
23. McKhann GM, Knopman DS, Chertkow H, et al.. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:263-269.
24. Haftenberger M, Schuit AJ, Tormo MJ, et al.. Physical activity of subjects aged 50-64 years involved in the European Prospective Investigation into Cancer and Nutrition (EPIC). Public Health Nutr 2002;5:1163-1176.
25. Nelissen N, Van Laere K, Thurfjell L, et al.. Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J Nucl Med 2009;50:1251-1259.
26. Lundqvist R, Lilja J, Thomas BA, et al.. Implementation and validation of an adaptive template registration method for 18F-flutemetamol imaging data. J Nucl Med 2013;54:1472-1478.
27. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-1364.
28. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al.. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009;65:403-413.
29. Robin X, Turck N, Hainard A, et al.. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 2011;12:77.
30. Benaglia T, Chauveau D, Hunter DR, Young D. Mixtools: an R package for analyzing finite mixture models. J Stat Softw 2009;32:1-29.
31. Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 2007;64:343-349.
32. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006;5:228-234.
33. Hertze J, Minthon L, Zetterberg H, Vanmechelen E, Blennow K, Hansson O. Evaluation of CSF biomarkers as predictors of Alzheimer's disease: a clinical follow-up study of 4.7 years. J Alzheimers Dis 2010;21:1119-1128.
34. Tapiola T, Alafuzoff I, Herukka SK, et al.. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 2009;66:382-389.
35. Thal DR, Attems J, Ewers M. Spreading of amyloid, tau, and microvascular pathology in Alzheimer's disease: findings from neuropathological and neuroimaging studies. J Alzheimers Dis 2014;42:S421-S429.
36. Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O. Cerebrospinal fluid levels of beta-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 2012;69:98-106.
37. De Meyer G, Shapiro F, Vanderstichele H, et al.. Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol 2010;67:949-956.
38. Le Bastard N, Coart E, Vanderstichele H, Vanmechelen E, Martin JJ, Engelborghs S. Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologically-confirmed dementia. J Alzheimers Dis 2013;33:117-131.
39. Klunk WE, Koeppe RA, Price JC, et al.. The Centiloid project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement 2015;11:1-15.e1-4.
40. Vanderstichele H, Bibl M, Engelborghs S, et al.. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimers Dement 2012;8:65-73.
|
Language: | English.
|
Document Type: | Article.
|
Journal Subset: | Clinical Medicine. Life & Biomedical Sciences.
|
ISSN: | 0028-3878
|
NLM Journal Code: | 0401060, nz0
|
DOI Number: | https://dx.doi.org/10.1212/WNL.0...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|